Please login to the form below

Not currently logged in
Email:
Password:

Kybella

This page shows the latest Kybella news and features for those working in and with pharma, biotech and healthcare.

Depression drug failure adds to Allergan's woes

Depression drug failure adds to Allergan's woes

The news adds to existing headwinds for the firm. It must write-down $1.6 bn in relation to its chin-fat injection Kybella, has called off the sale of its

Latest news

  • Allergan adds Zeltiq to M&A roster in $2.48n deal Allergan adds Zeltiq to M&A roster in $2.48n deal

    Other deals in the aesthetics sector include Allergan's $2.1bn purchase of Kythera in 2015, bringing in double chin-reducing therapy Kybella (deoxycholic acid), and the takeover of regenerative medicine

  • Allergan buys regenerative medicine firm LifeCell for $2.9bn Allergan buys regenerative medicine firm LifeCell for $2.9bn

    Those are headed by blockbuster wrinkle treatment Botox but also include Kybella - bought along with Kythera last year for $2.1bn - for reducing double chins and dermal filler Juvederm.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... Kybella. submental contouring (double chin).

  • Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

    Kybella (deoxycholic acid) was approved by the FDA in April and is administered by injection into the chin in order to break down "submental" fat. ... The company's chief executive Brent Saunders also suggested Allergan would be able to speed up the

  • Kythera bags FDA approval for double chin therapy Kythera bags FDA approval for double chin therapy

    Perhaps mindful that Kybella could also be a target, Kythera is launching the product with a holographic label that will make it easier for healthcare practitioners to identify genuine product. ... Kythera has also filed for approval of Kybella in Canada,

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    When Kybella  is injected into subcutaneous fat, it causes the destruction of fat cells and, once destroyed, these cells cannot store or accumulate fat. ... Kythera Biopharmaceuticals/ Allergan. Rx aesthetic medicine products - incl Kybella  for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics